Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.48 |
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251016 | 0.91 | KDR (0.53) | FGFR1KDRF10 | |
| SCHEMBL5252843 | 0.88 | FGFR1 (0.54) | FGFR1KDRF10USP1BACE1 | |
| SCHEMBL5248795 | 0.88 | KDR (0.53) | FGFR1KDRUSP1SYKKMT2A | |
| SCHEMBL5247284 | 0.86 | KDR (0.63) | FGFR1KDRF10USP1BACE1 | |
| Hydrochloric Acid SCHEMBL5251701 | 0.86 | KDR (0.62) | FGFR1KDRF10USP1BACE1 | |
| SCHEMBL5249777 | 0.81 | FGFR1 (0.51) | FGFR1KDRUSP1 | |
| SCHEMBL5252076 | 0.79 | KDR (0.67) | FGFR1KDRF10 | |
| Hydrochloric Acid SCHEMBL5248990 | 0.78 | KDR (0.66) | FGFR1KDRF10 | |
| SCHEMBL5249037 | 0.78 | FGFR1 (0.47) | FGFR1KDRUSP1TAS2R8GAA | |
| SCHEMBL5253145 | 0.77 | KDR (0.62) | FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |